Methods and systems using C4 gene copy number and cell-bound complement activation products for identification of lupus and pre-lupus

Patent metadata

Field	Value
Publication number	US-12130288-B2
Application number	US-201716303345-A
Country	US
Kind code	B2
Filing date	May 24, 2017
Priority date	May 24, 2016
Publication date	Oct 29, 2024
Grant date	Oct 29, 2024

Abstract

Cell-bound complement activation product (CB-CAP) profiling is combined with determination of C4 gene copy number as biomarkers for lupus and/or pre-lupus diagnosis and monitoring.

First claim

The invention claimed is:

1. A method of obtaining one or more corrected cell-bound complement activation product (CB-CAP) levels for a blood sample from a patient, the method comprising:
(a) measuring the number of C4 gene copies in a genomic DNA sample from the patient and detecting a reduced number of C4 gene copies in a genomic DNA sample from the patient compared to a C4 gene copy number threshold value;
(b) performing one or more cell-bound complement activation product (CB-CAP) assays on a blood sample from the patient to generate blood sampling data for the patient, wherein the one or more CB-CAP assays comprise a panel of assays using monoclonal antibodies specifically reactive with at least one of the following CB-CAPs: E-C4d, R-C4d, T-C4d, B-C4d, M-C4d, G-C4d, P-C4d, Eos-C4d, and Baso-C4d, and wherein the blood sampling data comprises one or more CB-CAP levels for one or more CB-CAPs in the patient;
(c) detecting that the one or more CB-CAP levels for the patient are not elevated as compared to a control; and
(d) multiplying one or more of the one or more CB-CAP levels for the patient by a correction factor to obtain one or more corrected CB-CAP levels for the patient.

2. The method of claim 1 , the method further comprising:
(a) detecting that the one or more corrected CB-CAP levels for the patient are elevated as compared to the control; and
(b) using the one or more corrected CB-CAP levels for the patient that are elevated in a determination of whether the patient has lupus or pre-lupus.

3. The method of claim 1 , comprising detecting a reduced number of C4 gene copies in a genomic DNA sample by a Southern blot assay, a qPCR assay, or DNA sequencing.

4. The method of claim 1 , wherein the one or more CB-CAP levels comprise measurements for one or more selected from the group consisting of T-C4d, B-C4d, and E-C4d.

5. The method of claim 2 , wherein the CB-CAPs for which one or more corrected CB-CAP levels are elevated as compared to the control include T-C4d, B-C4d, or both.

6. The method of claim 5 , wherein the CB-CAPs for which one or more corrected CB-CAP levels are elevated as compared to the control include one or more of E-C4d, R-C4d, P-C4d, and M-C4d.

7. The method of claim 1 , wherein identifying the correction factor comprises one or more of the following:
(a) identifying a multiplier equal to a ratio of a mean normal C4 gene copy number to the patient's reduced C4 gene copy number;
(b) accessing a table of correction factors and selecting, from the table, a correction factor that is associated with a CB-CAP; or
(c) using a standard correction factor that is also used for other patients.

8. The method of claim 1 , wherein the number of C4 gene copies comprises a C4A gene copy number, a C4B gene copy number, or both.

9. The method of claim 1 , wherein determining the C4 gene copy number threshold value comprises:
(a) identifying a mean or median gene copy number for a segment of patients in a control; and
(b) setting the C4 gene copy number threshold equal to one or more standard deviations from the identified mean or median gene copy number.

10. The method of claim 2 , wherein each instance of determining that the patient has lupus or pre-lupus comprises:
(a) if the patient meets at least a threshold level of classification criteria for lupus, determining that the patient has lupus; and
(b) if the patient does not meet at least the threshold level of classification criteria for lupus but meets at least one of the criteria, determining that the patient has pre-lupus.

11. The method of claim 10 , wherein the classification criteria are selected from the group consisting of serositis; oral ulcers; arthritis; photosensitivity; blood disorders; renal involvement; antinuclear antibodies; immunologic phenomena; neurologic disorder; malar rash; and discoid rash.

Assignees

• Allegheny Singer Res Institute
• Res Inst Nationwide Childrens Hospital

Inventors

• Ahearn Joseph M
• Liu Chau-Ching
• Manzi Susan M
• Yu C Yung

Classifications

• C12Q2600/158

  Expression markers · CPC title

• G16H10/40

  for data related to laboratory analysis, e.g. patient specimen analysis · CPC title

• G16H50/30

  for calculating health indices; for individual health risk assessment · CPC title

• C12Q1/68 Primary

  involving nucleic acids · CPC title

• G01N2800/50

  Determining the risk of developing a disease · CPC title